HUTCHMED completes enrolment in phase 3 trial for lung cancer
Ella Day | August 21, 2025 | News story | Research and Development | HUTCHMED, Oncology, clinical trial, lung cancer, non-small cell lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use of ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) as a first-line treatment for certain lung cancer patients in China. The final patient was enrolled on 18 August 2025.
The study is focused on people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours carry both an EGFR mutation and MET overexpression. These genetic alterations are known to drive resistance to existing targeted therapies.
SANOVO is comparing the combination of ORPATHYS and TAGRISSO against TAGRISSO alone, which is a current standard of care. Its primary endpoint is progression-free survival, with other measures including overall survival, response rates and safety.
The results from the trial are anticipated in the latter half of 2026 and could support a supplementary New Drug Application to China’s National Medical Products Administration if positive.
Michael Shi, head of R&D and chief medical officer of HUTCHMED, said: “Completing enrolment in SANOVO marks an important milestone in our global development programme for savolitinib. This study is designed to address a major unmet medical need for patients whose cancers develop resistance to targeted therapies.”
Co-developed by HUTCHMED and AstraZeneca, ORPATHYS is already approved in China for certain lung cancers. TAGRISSO is widely used for EGFR-mutated NSCLC globally.
Ella Day
21/8/25
Related Content
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …
Graphene-based biosensor to support new lung cancer screening test
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …
